Morgan Stanley’s Kindred Biosciences, Inc. KIN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-706,114
| Closed | -$6.47M | – | 8204 |
|
|
2021
Q2 | $6.47M | Buy |
706,114
+626,333
| +785% | +$3.64M | ﹤0.01% | 3500 |
|
|
2021
Q1 | $397K | Sell |
79,781
-93,678
| -54% | -$452K | ﹤0.01% | 5284 |
|
|
2020
Q4 | $747K | Buy |
173,459
+42,958
| +33% | +$175K | ﹤0.01% | 4829 |
|
|
2020
Q3 | $560K | Buy |
130,501
+82,548
| +172% | +$345K | ﹤0.01% | 4579 |
|
|
2020
Q2 | $216K | Sell |
47,953
-1,685,206
| -97% | -$7.53M | ﹤0.01% | 5045 |
|
|
2020
Q1 | $6.93M | Sell |
1,733,159
-9,256
| -0.5% | -$78.6K | ﹤0.01% | 2132 |
|
|
2019
Q4 | $14.8M | Sell |
1,742,415
-77,501
| -4% | -$605K | ﹤0.01% | 1965 |
|
|
2019
Q3 | $12.5M | Sell |
1,819,916
-82,045
| -4% | -$602K | ﹤0.01% | 1902 |
|
|
2019
Q2 | $15.8M | Buy |
1,901,961
+765,748
| +67% | +$6.61M | ﹤0.01% | 1691 |
|
|
2019
Q1 | $10.4M | Sell |
1,136,213
-686,892
| -38% | -$6.98M | ﹤0.01% | 2006 |
|
|
2018
Q4 | $20M | Sell |
1,823,105
-345,454
| -16% | -$4.35M | 0.01% | 1459 |
|
|
2018
Q3 | $30.3M | Buy |
2,168,559
+7,438
| +0.3% | +$101K | 0.01% | 1319 |
|
|
2018
Q2 | $23M | Sell |
2,161,121
-2,544
| -0.1% | -$24.8K | 0.01% | 1508 |
|
|
2018
Q1 | $18.7M | Buy |
2,163,665
+3,200
| +0.1% | +$28.1K | 0.01% | 1730 |
|
|
2017
Q4 | $20.4M | Buy |
2,160,465
+16,833
| +0.8% | +$132K | 0.01% | 1642 |
|
|
2017
Q3 | $16.8M | Buy |
2,143,632
+39,094
| +2% | +$293K | 0.01% | 1736 |
|
|
2017
Q2 | $18.1M | Buy |
2,104,538
+76,978
| +4% | +$552K | 0.01% | 1622 |
|
|
2017
Q1 | $14.3M | Buy |
2,027,560
+226,822
| +13% | +$1.42M | ﹤0.01% | 1864 |
|
|
2016
Q4 | $7.65M | Buy |
1,800,738
+1,776,239
| +7,250% | +$8.6M | ﹤0.01% | 2546 |
|
|
2016
Q3 | $122K | Sell |
24,499
-3,620
| -13% | -$15.3K | ﹤0.01% | 5228 |
|
|
2016
Q2 | $100K | Buy |
28,119
+4,756
| +20% | +$17.5K | ﹤0.01% | 5242 |
|
|
2016
Q1 | $80K | Buy |
23,363
+622
| +3% | +$2.2K | ﹤0.01% | 5418 |
|
|
2015
Q4 | $78K | Buy |
22,741
+1,232
| +6% | +$5.71K | ﹤0.01% | 5533 |
|
|
2015
Q3 | $112K | Sell |
21,509
-4,925
| -19% | -$30.4K | ﹤0.01% | 5376 |
|
|
2015
Q2 | $180K | Sell |
26,434
-1,160
| -4% | -$8.23K | ﹤0.01% | 5298 |
|
|
2015
Q1 | $197K | Sell |
27,594
-104,496
| -79% | -$720K | ﹤0.01% | 5215 |
|
|
2014
Q4 | $984K | Sell |
132,090
-254,690
| -66% | -$2.16M | ﹤0.01% | 4162 |
|
|
2014
Q3 | $3.58M | Buy |
386,780
+253,157
| +189% | +$3.42M | ﹤0.01% | 2934 |
|
|
2014
Q2 | $2.49M | Buy |
133,623
+45,504
| +52% | +$773K | ﹤0.01% | 3305 |
|
|
2014
Q1 | $1.63M | Buy |
88,119
+87,619
| +17,524% | +$1.67M | ﹤0.01% | 3601 |
|
|
2013
Q4 | $6K | Buy |
+500
| New | +$5.96K | ﹤0.01% | 6130 |
|
Other funds holding KIN
Morgan Stanley's KIN Position: Q3 2021 in Review
Morgan Stanley sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 706,114 shares — an estimated $6.47M sold.
Morgan Stanley first reported a position in KIN in Q4 2013 and held it in 31 quarters. The position peaked at $30.3M in Q3 2018. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.
- Morgan Stanley reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Morgan Stanley sold 706,114 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $6.47M.
- Morgan Stanley first reported a position in Kindred Biosciences, Inc. in Q4 2013 and held it in 31 quarters.
- Morgan Stanley's Kindred Biosciences, Inc. position peaked at $30.3M in Q3 2018.
- 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.
Based on Morgan Stanley's 13F filing for Q3 2021, filed 15 Nov 2021.